Laboratorio Emotest s.r.l.

# MONTHLY CLINICAL CHEMISTRY

## CYCLE 20 SAMPLE 1

**Explanation of codes used in this report**

R - Results removed due to reconstitution error
N - No result returned
C - Result corrected

Authorised by: Stephen Doherty, RIQAS Manager | Issue No: 1 | Issue Date: 09/02/2023

Randox Laboratories Limited
55 Diamond Road
CRUMLIN BT29 4QY
Tel: +44 (0)28 9445 4399
Fax: +44 (0)28 9445 4398
Email: mail@riqas.com



RIQAS

UKAS PROFICIENCY TESTING 0010

# Albumin, g/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 4802 | 2.970 | 5.3 | 0.00 | 0.16 | 391 |
| Bromocresol Purple | 464 | 2.823 | 4.2 | 0.01 | 0.15 | 41 |
| Abbott Architect c systems | 25 | 2.871 | 2.3 | 0.02 | 0.16 | 5 |

| | | | |
|---|---|---|---|
| Your Result | 2.700 | SDI | -1.09 |
| | | RMSDI | Too Few |
| Mean for Comparison | 2.871 | TS | 68 |
| | | RMTS | Too Few |
| | | %DEV | -6.0 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 9.00% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Bromocresol Green | 3910 | 2.990 | 5.1 | 0.00 |
| Bromocresol Purple | 464 | 2.823 | 4.2 | 0.01 |
| Ortho Vitros MicroSlide Systems | 204 | 2.933 | 3.5 | 0.01 |
| Agappe - Bromocresol Green | 56 | 3.140 | 4.4 | 0.02 |
| Abbott Alinity Albumin BCG 2 | 34 | 2.857 | 1.7 | 0.01 |
| Other Dry Chemistry | 37 | 3.405 | 4.6 | 0.03 |
| Turbidimetric Assays | 28 | 2.976 | 7.1 | 0.05 |
| Abbott Architect Albumin BCG 2 | 19 | 2.869 | 1.6 | 0.01 |
| Abbott Architect Albumin BCP 2 | 10 | 2.693 | 2.2 | 0.02 |
| Nephelometric Assays | 5 | 2.972 | 5.8 | 0.10 |
| Abbott Alinity Albumin BCP 2 | 4 | 2.630 | 3.9 | 0.06 |
| Vitros DT60/DT60 II/DTSC II | 2 | 2.930 | 3.4 | 0.09 |
| Electrophoresis | 2 | 2.985 | 6.4 | 0.17 |




TDPA = 9%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Alkaline Phosphatase, U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 4144 | 342.350 | 10.9 | 0.72 | 38.50 | 359 |
| Abbott Architect Alkaline Phosphatase 2 | 10 | 355.591 | 4.0 | 5.69 | 39.99 | 1 |
| Abbott Architect c systems | 10 | 355.591 | 4.0 | 5.69 | 39.99 | 1 |

| | | | |
|---|---|---|---|
| Your Result | 304.000 | SDI | -1.29 |
| | | RMSDI | Too Few |
| Mean for Comparison | 355.591 | TS | 61 |
| | | RMTS | Too Few |
| | | %DEV | -14.5 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 18.50% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| AMP optimised to IFCC | 1713 | 350.238 | 9.3 | 0.99 |
| Roche AMP buffer IFCC | 1020 | 323.629 | 4.0 | 0.50 |
| Diethanolamine buffer, DEA | 371 | 427.796 | 14.6 | 4.04 |
| AMP non-optimised | 217 | 349.115 | 8.8 | 2.62 |
| Ortho Vitros MicroSlide Systems | 216 | 283.674 | 5.4 | 1.30 |
| Siemens/Dade Dimension AMP buffer | 205 | 320.001 | 3.0 | 0.84 |
| Beckman AMP (Calibrator) | 112 | 394.756 | 5.8 | 2.68 |
| Colorimetric | 88 | 343.048 | 9.4 | 4.30 |
| Other AMP kits | 40 | 338.353 | 6.1 | 4.07 |
| Agappe - DGKC-SCE | 39 | 428.068 | 3.5 | 2.97 |
| Other Dry Chemistry | 38 | 377.160 | 10.3 | 7.86 |
| Abbott Alinity Alkaline Phosphatase 2 | 14 | 363.929 | 3.3 | 4.05 |
| Beckman AMP (Extinction Coeff) | 13 | 379.878 | 5.6 | 7.32 |
| Abbott Architect Alkaline Phosphatase 2 | 10 | 355.591 | 4.0 | 5.69 |
| AMP optimised to NVKC/SFBC | 6 | 400.290 | 13.0 | 26.65 |
| Fuji Dri-Chem JSCC | 5 | 380.500 | 5.6 | 11.94 |
| AMPD optimised to JSCC | 3 | 361.533 | 20.6 | 53.80 |
| Vitros DT60/DT60 II/DTSC II | 2 | 282.000 | 1.0 | 2.50 |
| AMP reduced interference | 2 | 364.500 | 8.3 | 26.87 |




TDPA = 18.5%












RIQAS

UKAS PROFICIENCY TESTING 0010

# ALT (GPT), U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5929 | 141.895 | 6.9 | 0.16 | 13.03 | 480 |
| Tris buffer without P5P | 3855 | 139.271 | 7.1 | 0.20 | 12.79 | 348 |
| Abbott Architect c systems | 206 | 139.167 | 3.5 | 0.42 | 12.78 | 19 |

| | | | |
|---|---|---|---|
| Your Result | 131.000 | SDI | -0.64 |
| | | RMSDI | Too Few |
| Mean for Comparison | 139.167 | TS | 91 |
| | | RMTS | Too Few |
| | | %DEV | -5.9 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 15.10% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Tris buffer without P5P | 3855 | 139.271 | 7.1 | 0.20 |
| Beckman Mod. IFCC Ref. without P5P | 686 | 144.956 | 3.7 | 0.26 |
| Tris buffer with P5P | 579 | 147.160 | 5.8 | 0.44 |
| Ortho Vitros MicroSlide Systems | 163 | 145.883 | 4.0 | 0.58 |
| Siemens/Dade standard nonIFCC correlated | 147 | 153.401 | 3.2 | 0.51 |
| Beckman IFCC Ref. with P5P | 87 | 144.657 | 3.8 | 0.74 |
| Agappe - IFCC | 75 | 149.545 | 5.9 | 1.27 |
| Ortho Vitros MicroSlide visible | 72 | 146.859 | 3.4 | 0.74 |
| Colorimetric | 52 | 146.214 | 6.9 | 1.74 |
| Other Dry Chemistry | 50 | 143.688 | 5.8 | 1.47 |
| Abbott Alinity ALT 2 | 24 | 132.155 | 3.8 | 1.29 |
| Phosphate buffer, DGKC | 22 | 144.283 | 9.0 | 3.45 |
| Tris buffer with P5P, NVKC | 18 | 149.494 | 9.5 | 4.17 |
| Tris buffer, SCE | 12 | 135.096 | 10.4 | 5.06 |
| Abbott Architect ALT 2 | 11 | 129.157 | 3.8 | 1.84 |
| Beckman (Extinction Coefficient) | 8 | 141.715 | 6.5 | 4.06 |
| Vitros DT60/DT60 II/DTSC II | 2 | 131.500 | 5.9 | 6.87 |




TDPA = 15.1%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Amylase, Pancreatic, U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 255 | 260.503 | 6.3 | 1.29 | 32.15 | 27 |
| Immunoinhibition, EPS substrate | 116 | 261.943 | 5.9 | 1.80 | 32.33 | 15 |
| Abbott Architect c systems | 17 | 266.001 | 8.8 | 7.10 | 32.83 | 1 |

| | | | |
|---|---|---|---|
| Your Result | 259.000 | SDI | -0.21 |
| | | RMSDI | Too Few |
| Mean for Comparison | 266.001 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -2.6 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 20.30% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Immunoinhibition, EPS substrate | 116 | 261.943 | 5.9 | 1.80 |
| Roche Liquid Stable pNPG7 | 94 | 253.210 | 2.8 | 0.93 |
| Amyloclastic Methods | 18 | 281.602 | 9.7 | 8.05 |
| Beckman Synchron/CX/LXi/DxC | 10 | 266.658 | 10.7 | 11.32 |
| Randox Liquid Stable pNPG7 | 6 | 284.050 | 2.9 | 4.17 |
| Other Dry Chemistry | 5 | 245.500 | 29.1 | 39.87 |















RIQAS

UKAS PROFICIENCY TESTING 0010

# Amylase, Total, U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 3698 | 296.421 | 8.7 | 0.53 | 30.46 | 389 |
| Abbott Architect Amylase 2 | 24 | 312.911 | 1.7 | 1.32 | 32.15 | 2 |
| Abbott Architect c systems | 22 | 313.175 | 1.6 | 1.36 | 32.18 | 2 |

| | | | |
|---|---|---|---|
| Your Result | 317.000 | SDI | 0.12 |
| | | RMSDI | Too Few |
| Mean for Comparison | 313.175 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 1.2 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 16.90% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Other 2-chloro-pNPG3 | 822 | 296.065 | 9.2 | 1.19 |
| Roche liquid stable pNPG7 | 769 | 278.146 | 2.1 | 0.27 |
| Siemens/Dade Behring 2-chloro-pNPG3 | 220 | 340.367 | 2.3 | 0.65 |
| Beckman Olympus blocked pNPG7 | 179 | 293.610 | 3.8 | 1.04 |
| Beckman CNPG3 (Master Cal) | 181 | 292.509 | 3.4 | 0.93 |
| Ortho Vitros MicroSlide Systems | 141 | 182.502 | 4.1 | 0.79 |
| Siemens - blocked pNPG7 | 144 | 312.479 | 6.1 | 1.97 |
| Other - blocked pNPG7 | 121 | 291.670 | 8.1 | 2.67 |
| Randox Liquid Ethylidene pNPG7 | 108 | 306.721 | 6.2 | 2.30 |
| Abbott Architect/Alinity cal factor 3431 | 102 | 314.993 | 2.9 | 1.13 |
| Other non blocked pNPG7 | 88 | 306.021 | 9.1 | 3.71 |
| Roche Integra 2-chloro-pNPG7 | 64 | 283.297 | 2.8 | 1.25 |
| Beckman Synchron AMY7 | 53 | 299.090 | 3.3 | 1.72 |
| Human CNPG3 (IFCC) | 52 | 303.058 | 7.6 | 3.99 |
| Agappe - CNPG3 | 53 | 308.369 | 5.1 | 2.69 |
| Other 2-chloro-pNP-linked sub. | 50 | 298.333 | 8.0 | 4.23 |
| Wiener Amilokit (AU/dl) | 47 | 211.236 | 18.8 | 7.24 |
| Abbott Architect/Alinity cal factor 3806 | 49 | 330.433 | 5.1 | 3.02 |
| pNP Maltotrioside substrates | 45 | 302.606 | 6.2 | 3.50 |
| BM/Roche Colorimetric pNPG7 | 38 | 278.206 | 2.8 | 1.56 |
| Beckman CNPG3 (Extinction Coeff) | 33 | 296.902 | 4.5 | 2.92 |




TDPA = 16.9%












RIQAS

UKAS PROFICIENCY TESTING 0010

# AST (GOT), U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5962 | 156.262 | 9.0 | 0.23 | 14.06 | 413 |
| Tris buffer without P5P | 3861 | 150.628 | 6.9 | 0.21 | 13.55 | 374 |
| Abbott Architect c systems | 200 | 143.468 | 3.3 | 0.42 | 12.91 | 28 |

| | | | |
|---|---|---|---|
| Your Result | 160.000 | SDI | 1.28 |
| | | RMSDI | Too Few |
| Mean for Comparison | 143.468 | TS | 61 |
| | | RMTS | Too Few |
| | | %DEV | 11.5 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 14.80% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Tris buffer without P5P | 3861 | 150.628 | 6.9 | 0.21 |
| Beckman Mod. IFCC Ref. without P5P | 700 | 160.476 | 3.9 | 0.29 |
| Tris buffer with P5P | 538 | 174.454 | 7.6 | 0.72 |
| Ortho Vitros MicroSlide visible | 224 | 190.690 | 4.5 | 0.71 |
| Siemens/Dade standard non IFCC corr. | 159 | 174.354 | 3.8 | 0.65 |
| Agappe - IFCC | 71 | 149.469 | 4.7 | 1.04 |
| Beckman IFCC Ref. with P5P | 67 | 162.156 | 5.4 | 1.33 |
| Other Dry Chemistry | 48 | 157.921 | 4.4 | 1.26 |
| Colorimetric | 49 | 154.667 | 7.9 | 2.19 |
| Abbott Alinity AST 2 | 25 | 165.564 | 6.9 | 2.86 |
| Phosphate buffer, DGKC | 24 | 159.188 | 10.9 | 4.44 |
| Tris buffer with P5P, NVKC | 17 | 155.209 | 8.2 | 3.87 |
| Abbott Architect AST 2 | 12 | 167.242 | 3.8 | 2.30 |
| Tris buffer, SCE | 11 | 151.124 | 5.4 | 3.07 |
| Beckman (Extinction Coefficient) | 7 | 161.471 | 6.0 | 4.61 |
| Vitros DT60/DT60 II/DTSC II | 3 | 152.333 | 0.8 | 0.83 |




TDPA = 14.8%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Bile Acids, umol/l

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 90 | 41.456 | 8.2 | 0.45 | 6.17 | 12 |
| Enzymatic Colorimetric | 82 | 41.049 | 8.2 | 0.47 | 6.11 | 9 |
| Abbott Architect c systems | 5 | 43.472 | 7.7 | 1.88 | 6.48 | 0 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 47.800 | SDI | 0.67 |
| | | RMSDI | Too Few |
| Mean for Comparison | 43.472 | TS | 89 |
| | | RMTS | Too Few |
| | | %DEV | 10.0 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 24.50% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Enzymatic Colorimetric | 82 | 41.049 | 8.2 | 0.47 |
| Enzymatic Colorimetric - Sentinel | 9 | 44.268 | 7.6 | 1.41 |




TDPA = 24.5%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Bilirubin, Direct, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 4660 | 1.517 | 17.5 | 0.00 | 0.24 | 352 |
| Diazo with Dichloroanaline | 407 | 1.632 | 10.7 | 0.01 | 0.26 | 40 |
| Abbott Architect c systems | 80 | 1.714 | 3.2 | 0.01 | 0.27 | 11 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 1.700 | SDI | -0.05 |
| | | RMSDI | Too Few |
| Mean for Comparison | 1.714 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -0.8 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 25.80% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Diazo with Sulphanilic Acid | 1710 | 1.561 | 15.6 | 0.01 |
| Dichlorophenyl Diazonium | 1271 | 1.474 | 15.8 | 0.01 |
| Diazo with Dichloroanaline | 407 | 1.632 | 10.7 | 0.01 |
| Roche DPD JG standardised | 311 | 1.686 | 5.0 | 0.01 |
| Oxidation to Biliverdin/Vanadate | 271 | 1.699 | 7.7 | 0.01 |
| Diazo/ Sulphanilic Siemens Dimension | 249 | 1.004 | 4.9 | 0.00 |
| Roche DPD Doumas standardised | 174 | 1.547 | 11.7 | 0.02 |
| Diazo/Sulphanilic Beckman DxC | 96 | 1.210 | 9.9 | 0.02 |
| Agappe - DIAZO | 56 | 0.970 | 16.4 | 0.03 |
| Other Dry Chemistry | 35 | 2.313 | 7.0 | 0.03 |
| Direct Spectrophotometry | 3 | 1.743 | 2.9 | 0.04 |
| Roche (US calibrator only) | 3 | 1.768 | 11.0 | 0.14 |















RIQAS

UKAS PROFICIENCY TESTING 0010

# Bilirubin, Total, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5183 | 4.840 | 8.2 | 0.01 | 0.47 | 393 |
| Diazo with Dichloroaniline | 443 | 5.088 | 6.9 | 0.02 | 0.49 | 43 |
| Abbott Architect c systems | 118 | 5.245 | 4.8 | 0.03 | 0.51 | 9 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 5.100 | SDI | -0.29 |
| | | RMSDI | Too Few |
| Mean for Comparison | 5.245 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -2.8 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 15.90% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Diazo with Sulphanilic Acid | 2016 | 4.917 | 7.8 | 0.01 |
| Dichlorophenyl Diazonium | 1104 | 4.599 | 6.9 | 0.01 |
| Diazonium ion | 492 | 4.622 | 7.6 | 0.02 |
| Diazo with Dichloroaniline | 443 | 5.088 | 6.9 | 0.02 |
| DPD (Beckman AU) | 424 | 4.991 | 3.0 | 0.01 |
| Oxidation to Biliverdin/Vanadate | 297 | 5.376 | 5.8 | 0.02 |
| Ortho Vitros MicroSlide System Total Bil | 192 | 4.489 | 5.8 | 0.02 |
| Agappe - TAB | 52 | 4.745 | 7.5 | 0.06 |
| Other Dry Chemistry | 45 | 4.528 | 3.9 | 0.03 |
| Nitrobenzenediazonium Salt | 24 | 4.745 | 6.0 | 0.07 |
| Abbott Alinity Total Bilirubin 2 | 9 | 5.138 | 6.9 | 0.15 |
| Agappe - DMSO | 10 | 4.826 | 6.0 | 0.11 |
| Direct Spectrophotometry | 9 | 4.764 | 9.1 | 0.18 |
| Vitros DT60/DT60 II Total Bil | 3 | 4.689 | 13.1 | 0.44 |
| Assel - DMSO | 2 | 5.945 | 8.2 | 0.43 |




TDPA = 15.9%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Calcium, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 4252 | 12.285 | 3.1 | 0.01 | 0.62 | 430 |
| Arsenazo | 1934 | 12.305 | 3.3 | 0.01 | 0.62 | 215 |
| Abbott Architect c systems | 218 | 12.063 | 2.7 | 0.03 | 0.61 | 19 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 12.300 | SDI | 0.39 |
| | | RMSDI | Too Few |
| Mean for Comparison | 12.063 | TS | 113 |
| | | RMTS | Too Few |
| | | %DEV | 2.0 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 8.30% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Arsenazo | 1934 | 12.305 | 3.3 | 0.01 |
| Cresolphthalein complexone | 1054 | 12.259 | 3.2 | 0.02 |
| NM-BAPTA | 807 | 12.342 | 2.0 | 0.01 |
| Ortho Vitros MicroSlide Systems | 217 | 12.035 | 2.6 | 0.03 |
| Ion selective electrode | 103 | 12.098 | 5.1 | 0.08 |
| Agappe - ARSENAZO | 40 | 12.289 | 2.8 | 0.07 |
| Other Dry Chemistry | 33 | 12.773 | 5.1 | 0.14 |
| Phosphonazo | 16 | 12.266 | 1.8 | 0.07 |
| Methylthymol blue | 13 | 12.189 | 3.7 | 0.16 |
| Atomic absorption | 4 | 12.793 | 2.5 | 0.20 |
| Agappe - OCPC | 3 | 11.493 | 6.7 | 0.55 |
| Optical Emission Spectroscopy | 2 | 11.800 | 15.6 | 1.62 |




TDPA = 8.3%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Chloride, mmol/l

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 3496 | 112.778 | 2.3 | 0.05 | 3.15 | 281 |
| ISE, indirect | 2293 | 112.472 | 1.9 | 0.06 | 3.15 | 187 |
| Abbott Architect c systems | 178 | 113.611 | 1.4 | 0.15 | 3.18 | 19 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 113.000 | SDI | -0.19 |
| | | RMSDI | Too Few |
| Mean for Comparison | 113.611 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -0.5 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 4.60% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| ISE, indirect | 2293 | 112.472 | 1.9 | 0.06 |
| ISE, direct | 896 | 113.540 | 2.8 | 0.13 |
| Ortho Vitros MicroSlide Systems | 141 | 115.213 | 2.0 | 0.24 |
| Colorimetric | 99 | 110.865 | 3.4 | 0.47 |
| Other Dry Chemistry | 32 | 112.578 | 2.7 | 0.68 |
| Agappe - THIOCYANATE | 15 | 114.489 | 2.4 | 0.90 |
| Optical Fluorescence | 5 | 124.800 | 6.2 | 4.33 |




TDPA = 4.6%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Cholesterol, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5497 | 289.310 | 3.8 | 0.18 | 15.12 | 554 |
| Abbott Architect Cholesterol 2 | 39 | 285.500 | 2.5 | 1.40 | 14.93 | 1 |
| Abbott Architect c systems | 35 | 286.671 | 2.2 | 1.32 | 14.98 | 2 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 286.000 | SDI | -0.04 |
| | | RMSDI | Too Few |
| Mean for Comparison | 286.671 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -0.2 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 8.60% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Cholesterol Oxidase - Abell Kendall | 3963 | 290.243 | 3.7 | 0.21 |
| Cholesterol Oxidase - IDMS | 748 | 292.655 | 3.4 | 0.46 |
| Siemens Dimension | 236 | 278.578 | 2.9 | 0.65 |
| Ortho Vitros MicroSlide Systems | 232 | 278.881 | 2.9 | 0.67 |
| Cholesterol Dehydrogenase | 116 | 290.975 | 4.4 | 1.49 |
| Agappe - CHOD-PAP | 72 | 290.718 | 2.5 | 1.08 |
| Other Dry Chemistry | 42 | 271.158 | 5.4 | 2.83 |
| Abbott Architect Cholesterol 2 | 39 | 285.500 | 2.5 | 1.40 |
| Abbott Alinity Cholesterol 2 | 32 | 286.557 | 1.7 | 1.09 |
| Dimension - non Siemens reagents | 6 | 283.487 | 6.3 | 9.10 |
| Vitros DT60/DT60 II/DTSC II | 2 | 278.462 | 0.8 | 1.92 |




TDPA = 8.6%












RIQAS

UKAS PROFICIENCY TESTING 0010

# CK, Total, U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 2786 | 521.977 | 6.5 | 0.80 | 38.08 | 309 |
| Abbott CK-NAC (IFCC) | 254 | 536.078 | 4.2 | 1.76 | 39.11 | 24 |
| Abbott Architect c systems | 119 | 522.993 | 4.5 | 2.69 | 38.15 | 13 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 517.000 | SDI | -0.16 |
| | | RMSDI | Too Few |
| Mean for Comparison | 522.993 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -1.1 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 12.00% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| CK-NAC (IFCC) | 1604 | 514.654 | 4.9 | 0.79 |
| Beckman CK-NAC (IFCC) | 384 | 556.172 | 4.4 | 1.56 |
| Abbott CK-NAC (IFCC) | 254 | 536.078 | 4.2 | 1.76 |
| Ortho Vitros MicroSlide Systems | 144 | 429.800 | 7.4 | 3.31 |
| CK-NAC substrate start (DGKC) | 138 | 510.291 | 6.2 | 3.38 |
| CK-NAC serum start (DGKC) | 81 | 525.826 | 8.4 | 6.11 |
| Creatine phosphate substrate start | 71 | 511.945 | 4.8 | 3.61 |
| Monothioglycerol | 45 | 555.884 | 4.1 | 4.24 |
| Agappe - IFCC/KINETIC | 33 | 524.533 | 4.9 | 5.64 |
| Other Dry Chemistry | 22 | 696.273 | 3.8 | 7.01 |
| Beckman CK-NAC (Extinction Coeff) | 11 | 551.157 | 5.0 | 10.41 |
| Dithioerythritol (DTE), IFCC correlated | 7 | 510.843 | 6.0 | 14.48 |




TDPA = 12%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Creatinine, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5946 | 4.314 | 6.3 | 0.00 | 0.33 | 521 |
| Alkaline picrate no deproteinisation | 1490 | 4.259 | 7.7 | 0.01 | 0.33 | 110 |
| Abbott Architect c systems | 152 | 4.525 | 3.6 | 0.02 | 0.35 | 18 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 4.880 | SDI | 1.02 |
| | | RMSDI | Too Few |
| Mean for Comparison | 4.525 | TS | 71 |
| | | RMTS | Too Few |
| | | %DEV | 7.8 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 12.60% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Alkaline picrate no deproteinisation | 1490 | 4.259 | 7.7 | 0.01 |
| Jaffe rate blanked | 1410 | 4.114 | 6.6 | 0.01 |
| Jaffe rate blanked comp. (-26umol/l) | 714 | 4.388 | 3.8 | 0.01 |
| Enzymatic UV method (340nm) | 327 | 4.488 | 4.1 | 0.01 |
| Jaffe rate comp. (-18umol/l) | 319 | 4.304 | 4.4 | 0.01 |
| Roche Creatinine Plus | 313 | 4.518 | 3.0 | 0.01 |
| Other enzymatic methods | 263 | 4.540 | 3.1 | 0.01 |
| IDMS traceable | 276 | 4.391 | 4.1 | 0.01 |
| Creatinine PAP method | 265 | 4.447 | 5.5 | 0.02 |
| Vitros, IDMS traceable | 152 | 4.507 | 3.2 | 0.01 |
| Alkaline picrate with deproteinisation | 133 | 4.222 | 6.0 | 0.03 |
| Other Dry Chemistry | 71 | 4.242 | 5.5 | 0.03 |
| Agappe - JAFFE'S KINETIC | 50 | 3.984 | 4.7 | 0.03 |
| Jaffe rate blanked comp. (-33umol/l) | 40 | 4.022 | 6.4 | 0.05 |
| Vitros DT60/DT60 II/DTSC II | 38 | 4.511 | 4.8 | 0.04 |
| Abbott Architect Creatinine 2 | 26 | 4.457 | 3.3 | 0.04 |
| Agappe - ENZYMATIC | 18 | 4.090 | 3.8 | 0.05 |
| Abbott Alinity Creatinine 2 | 21 | 4.467 | 2.8 | 0.03 |




TDPA = 12.6%












RIQAS

UKAS PROFICIENCY TESTING 0010

# GGT, U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 4080 | 168.243 | 7.2 | 0.24 | 18.31 | 397 |
| Gamma glut.-3-carb.-4-nitro. | 716 | 162.074 | 7.0 | 0.53 | 17.64 | 59 |
| Abbott Architect c systems | 79 | 164.412 | 4.7 | 1.09 | 17.89 | 8 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 167.000 | SDI | 0.14 |
| | | RMSDI | Too Few |
| Mean for Comparison | 164.412 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 1.6 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 17.90% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Gamma glut'3-carb'4-nitro(IFCC) | 2747 | 168.444 | 5.8 | 0.23 |
| Gamma glut.-3-carb.-4-nitro. | 716 | 162.074 | 7.0 | 0.53 |
| Siemens Dimension | 157 | 199.303 | 5.1 | 1.02 |
| Ortho Vitros MicroSlide Systems | 155 | 198.766 | 3.2 | 0.63 |
| Gamma glutamyl-4-nitroanilide | 83 | 161.727 | 9.3 | 2.07 |
| DCL, gamma glut.-3-carb.-4-nitro. | 73 | 164.581 | 5.9 | 1.42 |
| Beckman Szasz (Extinction Coeff.) | 47 | 169.411 | 6.5 | 2.00 |
| Agappe - SZASZ KINETIC | 47 | 175.581 | 3.7 | 1.18 |
| Abbott Alinity GGT 2 | 40 | 169.518 | 3.2 | 1.06 |
| Other Dry Chemistry | 33 | 141.788 | 5.9 | 1.83 |
| Abbott Architect GGT 2 | 10 | 167.660 | 1.6 | 1.08 |
| Vitros, DT60/DT60 II/DTSC II | 3 | 201.667 | 1.6 | 2.32 |
| Randox Colorimetric | 2 | 155.500 | 5.0 | 6.87 |




TDPA = 17.9%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Glucose, mmol/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5986 | 15.601 | 3.6 | 0.01 | 0.81 | 561 |
| Hexokinase | 3115 | 15.659 | 2.4 | 0.01 | 0.81 | 280 |
| Abbott Architect c systems | 238 | 15.719 | 2.2 | 0.03 | 0.81 | 22 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 283.000 | SDI | 329.04 |
| | | RMSDI | Too Few |
| Mean for Comparison | 15.719 | TS | 10 |
| | | RMTS | Too Few |
| | | %DEV | 999.0 |
| | | RM%DEV | Too Few |

Acceptable limits derived from Biological Variation N/A

Acceptable limits of performance for RIQAS 8.50%

SDI in bottom 5% of peer group

TS & %DEV outside limits




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Hexokinase | 3115 | 15.659 | 2.4 | 0.01 |
| Glucose oxidase | 2451 | 15.576 | 5.0 | 0.02 |
| Ortho Vitros MicroSlide Systems | 218 | 14.770 | 2.3 | 0.03 |
| Agappe - GOD-PAP | 70 | 15.837 | 3.2 | 0.07 |
| Glucose dehydrogenase | 52 | 15.654 | 5.2 | 0.14 |
| Other Dry Chemistry | 44 | 14.994 | 3.0 | 0.08 |
| GOD/02-Beckman method | 26 | 15.970 | 4.0 | 0.16 |
| Oxygen electrode | 9 | 15.600 | 1.2 | 0.08 |
| Pyranose Oxidase / Peroxidase | 4 | 16.246 | 5.3 | 0.54 |
| Vitros, DT60/DT60 II | 3 | 15.772 | 13.3 | 1.52 |




TDPA = 8.5%












RIQAS

UKAS PROFICIENCY TESTING 0010

# HDL-Cholesterol, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 4371 | 99.796 | 12.7 | 0.24 | 12.80 | 310 |
| HDL Ultra/Accel Selective Detergent | 476 | 96.153 | 5.2 | 0.28 | 12.33 | 53 |
| Abbott Architect c systems | 175 | 96.439 | 4.6 | 0.42 | 12.37 | 16 |

| | | | |
|---|---|---|---|
| Your Result | 96.000 | SDI | -0.04 |
| | | RMSDI | Too Few |
| Mean for Comparison | 96.439 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -0.5 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 21.10% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Direct HDL, Roche 4th gen. | 1151 | 112.030 | 4.5 | 0.18 |
| Direct HDL, Clearance method | 882 | 89.365 | 12.9 | 0.48 |
| Direct HDL, Immunoseparation | 691 | 94.529 | 8.8 | 0.39 |
| HDL Ultra/Accel Selective Detergent | 476 | 96.153 | 5.2 | 0.28 |
| Direct HDL, PEGME | 446 | 95.981 | 20.0 | 1.13 |
| Direct HDL, PPD | 311 | 99.935 | 9.8 | 0.69 |
| Vitros dHDL, PTA/MgCl2 direct precip. | 172 | 94.660 | 6.8 | 0.61 |
| Agappe - SELECTIVE INHIBITION | 56 | 109.455 | 6.2 | 1.12 |
| Other Dry Chemistry | 45 | 101.435 | 10.1 | 1.92 |
| Vitros, Magnetic HDL | 22 | 96.391 | 6.0 | 1.53 |
| Vitros 5.1 FS Microtip assay | 13 | 92.050 | 7.0 | 2.23 |















RIQAS

UKAS PROFICIENCY TESTING 0010

# Iron, ug/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 2735 | 219.829 | 4.7 | 0.25 | 13.36 | 242 |
| Colorimetric without ppt. | 2169 | 220.884 | 4.2 | 0.25 | 13.43 | 190 |
| Abbott Architect c systems | 121 | 231.371 | 3.5 | 0.93 | 14.07 | 11 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 224.000 | SDI | -0.52 |
| | | RMSDI | Too Few |
| Mean for Comparison | 231.371 | TS | 100 |
| | | RMTS | Too Few |
| | | %DEV | -3.2 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 10.00% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Colorimetric without ppt. | 2169 | 220.884 | 4.2 | 0.25 |
| Colorimetric with ppt. | 324 | 218.030 | 4.7 | 0.70 |
| Ortho Vitros MicroSlide Systems | 153 | 202.791 | 5.1 | 1.04 |
| Other method with blank | 22 | 224.056 | 2.7 | 1.64 |
| Abbott Alinity Iron 2 | 15 | 234.413 | 2.3 | 1.74 |
| Other method without blank | 13 | 220.516 | 3.8 | 2.91 |
| Agappe - CHROMAZUROL | 10 | 232.538 | 7.9 | 7.26 |
| Other Dry Chemistry | 8 | 210.145 | 8.3 | 7.70 |
| Abbott Architect Iron 2 | 7 | 234.884 | 2.5 | 2.81 |
| Optical Emission Spectroscopy | 5 | 215.858 | 6.6 | 7.92 |




TDPA = 10%












RIQAS

UKAS PROFICIENCY TESTING 0010

# LD (LDH), U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 2706 | 406.223 | 24.7 | 2.41 | 31.61 | 334 |
| L to P, IFCC | 1765 | 373.782 | 3.8 | 0.43 | 29.09 | 168 |
| Abbott Architect c systems | 119 | 355.290 | 3.5 | 1.43 | 27.65 | 12 |

| | | | |
|---|---|---|---|
| Your Result | 360.000 | SDI | 0.17 |
| | | RMSDI | Too Few |
| Mean for Comparison | 355.290 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 1.3 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 12.80% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| L to P, IFCC | 1765 | 373.782 | 3.8 | 0.43 |
| P to L, German methods | 261 | 741.407 | 6.5 | 3.72 |
| Lactate to Pyruvate methods | 192 | 370.389 | 10.0 | 3.35 |
| Ortho Vitros IFCC Traceable | 111 | 400.942 | 2.9 | 1.40 |
| P to L, Scandinavian & Dutch | 98 | 765.744 | 7.8 | 7.55 |
| P to L, SFBC / SEQC | 73 | 755.681 | 7.4 | 8.19 |
| L to P Siemens/Dade, Non-IFCC | 56 | 369.744 | 2.8 | 1.71 |
| L to P Beckman (Extinction Coeff) | 54 | 376.226 | 5.6 | 3.56 |
| Agappe - SCE | 33 | 789.222 | 2.3 | 3.88 |
| Ortho Vitros MicroSlide Systems | 34 | 401.340 | 3.0 | 2.62 |
| Other Dry Chemistry | 24 | 373.875 | 5.7 | 5.42 |
| Abbott Alinity LD 2 | 15 | 361.467 | 2.1 | 2.42 |
| Pyruvate 1.4 mM - Beckman LD-P | 3 | 848.000 | 16.4 | 100.63 |
| Abbott Architect LD 2 | 5 | 356.069 | 2.1 | 4.19 |




TDPA = 12.8%












RIQAS

UKAS PROFICIENCY TESTING 0010

# LDL-Cholesterol (Pilot), mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 1308 | 139.629 | 13.2 | 0.63 | 17.48 | 87 |
| Selective detergent methods | 475 | 136.737 | 12.6 | 0.99 | 17.12 | 24 |
| Abbott Architect c systems | 34 | 115.258 | 3.0 | 0.74 | 14.43 | 7 |

| | | | |
|---|---|---|---|
| Your Result | 114.000 | SDI | -0.09 |
| | | RMSDI | Too Few |
| Mean for Comparison | 115.258 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -1.1 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 20.60% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Selective detergent methods | 475 | 136.737 | 12.6 | 0.99 |
| Other direct methods | 470 | 138.730 | 12.6 | 1.01 |
| Sel.detergent Beckman OSR6x83 | 164 | 154.640 | 6.8 | 1.02 |
| Calculated | 94 | 136.011 | 11.9 | 2.09 |
| Ortho Vitros MicroSlide Systems | 22 | 95.977 | 6.2 | 1.59 |
| Sel.detergent Beckman OSR6x96 | 23 | 123.987 | 22.0 | 7.12 |
| Agappe - SELECTIVE SOLUBILISATION | 21 | 150.504 | 12.0 | 4.92 |
| Other Precipitation methods | 14 | 133.044 | 12.2 | 5.40 |
| Polyvinyl Sulphate Precipitation | 11 | 171.971 | 23.6 | 15.30 |
| Heparin precipitation | 8 | 127.299 | 18.6 | 10.45 |
| Other Dry Chemistry | 5 | 118.827 | 27.2 | 18.05 |
| Zwitterionic Detergent | 2 | 94.231 | 20.2 | 16.82 |




TDPA = 20.6%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Lipase, U/l @ 37°C

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 1513 | 68.364 | 17.7 | 0.39 | 10.68 | 220 |
| Other Colorimetric | 718 | 66.231 | 13.3 | 0.41 | 10.35 | 68 |
| Abbott Architect c systems | 79 | 60.075 | 3.9 | 0.33 | 9.39 | 11 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 60.000 | SDI | -0.01 |
| | | RMSDI | Too Few |
| Mean for Comparison | 60.075 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -0.1 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 25.70% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Other Colorimetric | 718 | 66.231 | 13.3 | 0.41 |
| Colorimetric Roche ACN(8)731/ID 0-100 | 323 | 69.388 | 4.7 | 0.23 |
| Colorimetric Roche ACN(8)789/ID 0-052 | 208 | 69.944 | 4.7 | 0.28 |
| Ortho Vitros MicroSlide Systems | 111 | 756.205 | 5.8 | 5.24 |
| Colorimetric Dade Dimension (LIPL Kit) | 60 | 243.938 | 12.2 | 4.79 |
| Roche Turbidimetric with colipase | 43 | 68.066 | 6.7 | 0.86 |
| Colorimetric Randox | 28 | 83.346 | 20.3 | 3.99 |
| Agappe - METHYL RESORUFIN | 22 | 61.861 | 18.2 | 2.99 |
| Other Turbidimetric with colipase | 21 | 62.650 | 11.8 | 2.02 |
| Colorimetric Dade Dimension (LIP Kit) | 6 | 65.367 | 7.4 | 2.47 |
| Other Dry Chemistry | 7 | 102.286 | 32.8 | 15.84 |
| Turbidimetric without colipase | 7 | 62.000 | 16.3 | 4.77 |
| Randox Turbidimetric with colipase | 5 | 72.240 | 30.5 | 12.31 |
| Colorimetric Sigma | 2 | 65.650 | 22.3 | 12.94 |
| Titrimetric | 2 | 62.850 | 1.9 | 1.06 |















RIQAS

UKAS PROFICIENCY TESTING 0010

# Lithium, mmol/l

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 198 | 2.051 | 5.9 | 0.01 | 0.15 | 25 |
| Spectrophotometric | 111 | 2.022 | 3.1 | 0.01 | 0.14 | 16 |
| Abbott Architect c systems | 10 | 2.036 | 5.3 | 0.04 | 0.14 | 0 |

| | | | |
|---|---|---|---|
| Your Result | 2.060 | SDI | 0.17 |
| | | RMSDI | Too Few |
| Mean for Comparison | 2.036 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 1.2 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 11.70% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Spectrophotometric | 111 | 2.022 | 3.1 | 0.01 |
| Ion selective electrode | 52 | 2.047 | 6.5 | 0.02 |
| Ortho Vitros MicroSlide Systems | 22 | 2.417 | 6.3 | 0.04 |
| Flame photometry | 8 | 2.026 | 8.2 | 0.07 |
| Atomic absorption | 5 | 2.205 | 8.9 | 0.11 |
| Other Dry Chemistry | 2 | 2.035 | 1.7 | 0.03 |




TDPA = 11.7%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Magnesium, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 2706 | 4.248 | 4.0 | 0.00 | 0.28 | 301 |
| Arsenazo | 64 | 4.241 | 4.0 | 0.03 | 0.28 | 7 |
| Abbott Architect c systems | 36 | 4.209 | 3.9 | 0.03 | 0.28 | 3 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 4.300 | SDI | 0.32 |
| | | RMSDI | Too Few |
| Mean for Comparison | 4.209 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 2.2 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 11.00% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Xylidyl Blue | 1416 | 4.241 | 4.2 | 0.01 |
| Enzymatic | 329 | 4.272 | 3.2 | 0.01 |
| Chlorphosphonazo III | 271 | 4.263 | 2.5 | 0.01 |
| Methylthymol blue | 208 | 4.272 | 3.0 | 0.01 |
| Ortho Vitros MicroSlide Systems | 172 | 4.304 | 3.3 | 0.01 |
| Calmagite | 120 | 4.118 | 5.9 | 0.03 |
| Arsenazo | 64 | 4.241 | 4.0 | 0.03 |
| Atomic absorption | 55 | 4.255 | 3.1 | 0.02 |
| Agappe - XYLIDYL BLUE | 28 | 3.819 | 4.9 | 0.04 |
| Other Dry Chemistry | 21 | 4.737 | 8.4 | 0.11 |
| Other magnesium dyes | 12 | 4.207 | 6.2 | 0.09 |




TDPA = 11%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Phosphate, Inorganic, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 2964 | 6.903 | 3.5 | 0.01 | 0.39 | 310 |
| Phosphomolybdate UV | 2407 | 6.903 | 3.5 | 0.01 | 0.39 | 255 |
| Abbott Architect c systems | 119 | 6.811 | 2.0 | 0.02 | 0.39 | 16 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 6.700 | SDI | -0.28 |
| | | RMSDI | Too Few |
| Mean for Comparison | 6.811 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -1.6 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 9.40% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Phosphomolybdate UV | 2407 | 6.903 | 3.5 | 0.01 |
| Phosphomolybdate enzymatic | 266 | 6.866 | 3.3 | 0.02 |
| Ortho Vitros MicroSlide Systems | 182 | 6.894 | 3.5 | 0.02 |
| Beckman PHOSm kit (365nm) | 42 | 6.830 | 3.3 | 0.04 |
| Agappe - PHOSPOHMOLYBDATE | 36 | 7.123 | 2.1 | 0.03 |
| Other Dry Chemistry | 13 | 7.303 | 2.2 | 0.06 |
| Other methods, no protein ppt | 5 | 7.088 | 1.8 | 0.07 |
| Other methods, with protein ppt | 2 | 6.728 | 2.1 | 0.13 |















RIQAS

UKAS PROFICIENCY TESTING 0010

# Potassium, mmol/l

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 3787 | 6.105 | 2.5 | 0.00 | 0.21 | 387 |
| ISE method - indirect | 2366 | 6.143 | 1.7 | 0.00 | 0.21 | 217 |
| Abbott Architect c systems | 187 | 6.109 | 1.6 | 0.01 | 0.21 | 15 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 6.100 | SDI | -0.04 |
| | | RMSDI | Too Few |
| Mean for Comparison | 6.109 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -0.1 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 5.60% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| ISE method - indirect | 2366 | 6.143 | 1.7 | 0.00 |
| ISE method - direct | 1168 | 5.990 | 3.9 | 0.01 |
| Ortho Vitros MicroSlide Systems | 173 | 6.064 | 2.0 | 0.01 |
| Colorimetric | 52 | 5.592 | 5.6 | 0.05 |
| Other Dry Chemistry | 30 | 6.052 | 2.2 | 0.03 |
| Agappe - ISE DIRECT | 21 | 5.986 | 1.4 | 0.02 |
| Flame photometry | 14 | 5.757 | 7.1 | 0.14 |
| Enzymatic | 6 | 6.052 | 2.2 | 0.07 |
| Turbidimetric | 7 | 6.040 | 7.1 | 0.20 |
| Optical Fluorescence | 6 | 6.137 | 0.5 | 0.02 |
| Vitros, DT60/DT60 II/DTE II | 3 | 6.033 | 1.0 | 0.04 |















RIQAS

UKAS PROFICIENCY TESTING 0010

# Protein, Total, g/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 4717 | 4.633 | 4.8 | 0.00 | 0.25 | 499 |
| Biuret reaction, end point | 4120 | 4.627 | 4.8 | 0.00 | 0.24 | 482 |
| Abbott Architect c systems | 184 | 4.681 | 2.6 | 0.01 | 0.25 | 21 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 4.800 | SDI | 0.48 |
| | | RMSDI | Too Few |
| Mean for Comparison | 4.681 | TS | 103 |
| | | RMTS | Too Few |
| | | %DEV | 2.5 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 8.70% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Biuret reaction, end point | 4120 | 4.627 | 4.8 | 0.00 |
| Ortho Vitros MicroSlide Systems | 196 | 4.674 | 2.4 | 0.01 |
| Biuret reaction, kinetic | 143 | 4.556 | 3.2 | 0.02 |
| Agappe - BIURET | 59 | 4.957 | 5.1 | 0.04 |
| Other Dry Chemistry | 45 | 4.677 | 4.0 | 0.04 |
| Biuret reaction, CX4/5/7 | 40 | 4.526 | 2.2 | 0.02 |
| Abbott Alinity Total Protein 2 | 33 | 4.706 | 1.6 | 0.02 |
| Abbott Architect total Protein 2 | 25 | 4.673 | 2.8 | 0.03 |
| Refractometry | 2 | 4.595 | 3.2 | 0.13 |




TDPA = 8.7%












RIQAS

UKAS PROFICIENCY TESTING 0010

# PSA, Total, ng/ml

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 528 | 17.386 | 18.6 | 0.18 | 2.62 | 57 |
| Abbott Architect/ Alinity | 67 | 14.743 | 8.5 | 0.19 | 2.22 | 4 |
| Abbott Architect i Systems | 43 | 14.965 | 9.6 | 0.27 | 2.26 | 2 |

| | | | |
|---|---|---|---|
| Your Result | 14.200 | SDI | -0.34 |
| | | RMSDI | Too Few |
| Mean for Comparison | 14.965 | TS | 119 |
| | | RMTS | Too Few |
| | | %DEV | -5.1 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 24.80% |
















| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Roche Cobas 4000/e411 | 85 | 18.068 | 10.0 | 0.24 |
| Abbott Architect/ Alinity | 67 | 14.743 | 8.5 | 0.19 |
| Monobind Inc ELISA / CLIA | 45 | 25.852 | 13.8 | 0.67 |
| SNIBE Maglumi analysers | 48 | 14.284 | 8.7 | 0.22 |
| Roche Cobas e601/602 | 42 | 18.221 | 5.1 | 0.18 |
| ELISA | 40 | 25.747 | 21.1 | 1.07 |
| bioMerieux, VIDAS TPSA | 37 | 17.814 | 7.4 | 0.27 |
| Beckman Access standardised to Hybritech | 24 | 20.066 | 9.0 | 0.46 |
| Tosoh AIA Series | 20 | 13.442 | 6.6 | 0.25 |
| Siemens Dimension | 16 | 17.545 | 4.4 | 0.24 |
| Ortho Vitros 3600/5600/ECi | 13 | 16.801 | 8.3 | 0.49 |
| Roche Cobas e402/e801 | 11 | 17.918 | 3.1 | 0.21 |
| Mindray CL-Series | 8 | 20.279 | 6.0 | 0.54 |
| Siemens Immulite 2000/2500, Total PSA | 8 | 16.469 | 10.3 | 0.75 |
| Siemens Centaur XP/XPT | 8 | 16.305 | 8.4 | 0.60 |
| Siemens Centaur CP | 7 | 16.321 | 13.7 | 1.05 |
| Ortho Vitros 3600/5600/ECi PSA II | 7 | 17.200 | 12.8 | 1.04 |
| Beckman DXI standardised to Hybritech | 7 | 18.836 | 10.0 | 0.89 |
| Roche Elecsys Modular E170 | 6 | 16.748 | 13.1 | 1.12 |
| Siemens Atellica IM | 6 | 15.925 | 9.3 | 0.76 |
| Siemens Immulite 1000, Total PSA | 5 | 15.580 | 6.4 | 0.55 |



RIQAS

UKAS PROFICIENCY TESTING 0010

# Sodium, mmol/l

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 3781 | 156.637 | 1.8 | 0.06 | 3.43 | 346 |
| ISE method - indirect | 2394 | 157.362 | 1.4 | 0.06 | 3.44 | 191 |
| Abbott Architect c systems | 181 | 157.113 | 1.3 | 0.18 | 3.44 | 23 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 156.000 | SDI | -0.32 |
| | | RMSDI | Too Few |
| Mean for Comparison | 157.113 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | -0.7 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 3.60% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| ISE method - indirect | 2394 | 157.362 | 1.4 | 0.06 |
| ISE method - direct | 1135 | 154.939 | 2.2 | 0.13 |
| Ortho Vitros MicroSlide Systems | 161 | 154.530 | 1.6 | 0.25 |
| Colorimetric | 42 | 152.422 | 2.3 | 0.68 |
| Other Dry Chemistry | 27 | 154.926 | 1.4 | 0.52 |
| Agappe - ISE DIRECT | 18 | 156.222 | 0.8 | 0.37 |
| Flame photometry | 13 | 154.923 | 3.1 | 1.66 |
| Enzymatic | 7 | 155.619 | 2.0 | 1.49 |
| Optical Fluorescence | 6 | 158.633 | 2.1 | 1.70 |
| Vitros, DT60/DT60 II/DTE II | 4 | 153.800 | 1.1 | 1.03 |




TDPA = 3.6%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Free T3, pg/ml

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 385 | 8.667 | 16.3 | 0.09 | 0.92 | 51 |
| Abbott Architect/ Alinity, 6 point cal | 36 | 7.807 | 5.4 | 0.09 | 0.83 | 4 |
| Abbott Architect i Systems | 22 | 7.867 | 6.3 | 0.13 | 0.83 | 1 |

| | | | |
|---|---|---|---|
| Your Result | 7.570 | SDI | -0.36 |
| | | RMSDI | Too Few |
| Mean for Comparison | 7.867 | TS | 116 |
| | | RMTS | Too Few |
| | | %DEV | -3.8 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 17.40% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Roche Cobas 4000/e411 | 68 | 9.432 | 5.5 | 0.08 |
| Roche Cobas e601/602 | 50 | 9.631 | 4.0 | 0.07 |
| BioMerieux VIDAS | 38 | 8.907 | 7.0 | 0.13 |
| Abbott Architect/ Alinity, 2 point cal | 39 | 7.812 | 6.2 | 0.10 |
| Abbott Architect/ Alinity, 6 point cal | 36 | 7.807 | 5.4 | 0.09 |
| Beckman Access/LXi725 | 29 | 5.951 | 7.1 | 0.10 |
| SNIBE Maglumi analysers | 15 | 9.850 | 5.4 | 0.17 |
| Ortho Vitros 3600/5600/ECi/XT 7600 | 16 | 19.102 | 4.5 | 0.27 |
| Siemens Dimension Exl LOCI | 12 | 9.431 | 1.2 | 0.04 |
| Roche Cobas e402/e801 | 14 | 9.558 | 3.6 | 0.11 |
| Tosoh AIA Series | 12 | 11.819 | 11.6 | 0.50 |
| Siemens Centaur XP/XPT | 10 | 8.824 | 5.6 | 0.20 |
| Beckman Dxl 600/800 | 9 | 5.205 | 10.9 | 0.24 |
| Mindray CL-Series | 7 | 8.672 | 7.1 | 0.29 |
| Siemens/DPC Immulite 2000/2500 | 7 | 4.743 | 13.4 | 0.30 |
| Siemens Atellica IM | 7 | 9.952 | 3.4 | 0.16 |
| ELISA | 5 | 7.350 | 26.8 | 1.10 |
| Siemens Centaur CP | 4 | 9.122 | 2.1 | 0.12 |
| Monobind Inc ELISA / CLIA | 3 | 4.687 | 9.2 | 0.31 |
| Roche Elecsys | 3 | 9.820 | 16.2 | 1.15 |
| Autobio CLIA | 2 | 9.897 | 2.8 | 0.24 |




TDPA = 17.4%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Free T4, ng/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 665 | 5.299 | 21.5 | 0.06 | 0.65 | 59 |
| Abbott Architect/ Alinity | 89 | 3.843 | 11.8 | 0.06 | 0.47 | 9 |
| Abbott Architect i Systems | 57 | 3.930 | 11.7 | 0.08 | 0.48 | 6 |

| | | | |
|---|---|---|---|
| Your Result | 4.190 | SDI | 0.54 |
| | | RMSDI | Too Few |
| Mean for Comparison | 3.930 | TS | 98 |
| | | RMTS | Too Few |
| | | %DEV | 6.6 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 20.10% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Roche Cobas 4000/e411 | 105 | 6.049 | 8.9 | 0.07 |
| Abbott Architect/ Alinity | 89 | 3.843 | 11.8 | 0.06 |
| Roche Cobas e601/ 602 | 57 | 5.983 | 5.8 | 0.06 |
| SNIBE Maglumi analysers | 54 | 5.703 | 5.5 | 0.05 |
| bioMerieux, VIDAS-FT4N Kit | 48 | 5.788 | 5.8 | 0.06 |
| Monobind Inc ELISA / CLIA | 46 | 3.227 | 8.6 | 0.05 |
| Beckman Access/LXi725 | 35 | 4.872 | 6.7 | 0.07 |
| Roche Cobas e402/e801 | 24 | 6.006 | 5.6 | 0.09 |
| Tosoh AIA Series | 25 | 6.128 | 7.6 | 0.12 |
| Ortho Vitros 3600/5600/ECi/XT/7600 | 10 | 6.986 | 0.6 | 0.02 |
| ELISA | 18 | 3.526 | 23.2 | 0.24 |
| Mindray CL-Series | 15 | 4.277 | 6.6 | 0.09 |
| Siemens Centaur XP/XPT | 13 | 5.060 | 9.4 | 0.16 |
| Siemens Dimension Exl LOCI | 12 | 6.538 | 2.1 | 0.05 |
| Siemens/DPC Immulite 2000/2500 | 12 | 5.670 | 4.7 | 0.10 |
| Beckman Dxl 600/800 | 14 | 5.263 | 5.5 | 0.10 |
| Siemens Centaur CP | 7 | 5.643 | 6.3 | 0.17 |
| Siemens Atellica IM | 8 | 5.357 | 5.1 | 0.12 |
| Siemens/DPC Immulite 1000 | 6 | 5.944 | 18.5 | 0.56 |
| Roche Elecsys | 6 | 5.502 | 4.4 | 0.12 |
| DiaSorin Liaison XL | 5 | 7.552 | 2.0 | 0.09 |




TDPA = 20.1%









# TSH, uU/ml

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 795 | 1.281 | 13.2 | 0.01 | 0.19 | 59 |
| Abbott Architect/ Alinity | 103 | 1.022 | 5.5 | 0.01 | 0.15 | 13 |
| Abbott Architect i Systems | 64 | 1.028 | 5.4 | 0.01 | 0.15 | 10 |

| | | | |
|---|---|---|---|
| Your Result | 1.070 | SDI | 0.28 |
| | | RMSDI | Too Few |
| Mean for Comparison | 1.028 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 4.0 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 23.90% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Roche Cobas 4000/e411 | 121 | 1.475 | 5.2 | 0.01 |
| Abbott Architect/ Alinity | 103 | 1.022 | 5.5 | 0.01 |
| Roche Cobas e601/ 602 | 64 | 1.428 | 2.8 | 0.01 |
| SNIBE Maglumi analysers | 60 | 1.283 | 4.4 | 0.01 |
| Monobind Inc ELISA / CLIA | 55 | 1.244 | 9.8 | 0.02 |
| Biomerieux VIDAS TSH | 49 | 1.330 | 5.4 | 0.01 |
| ELISA | 36 | 1.183 | 18.6 | 0.05 |
| Ortho Vitros 3600/5600/ECi/XT 7600 | 25 | 1.216 | 4.2 | 0.01 |
| Tosoh AIA Series | 29 | 1.250 | 7.9 | 0.02 |
| Beckman DXI600/800/ Access 2 (3rd IS) | 25 | 1.207 | 6.5 | 0.02 |
| Beckman Access/LXi725 hyper TSH 3rd gen. | 24 | 1.218 | 5.7 | 0.02 |
| Roche Cobas e402/e801 | 23 | 1.398 | 3.0 | 0.01 |
| Mindray CL-Series | 14 | 1.668 | 8.0 | 0.04 |
| Siemens Dimension Exl LOCI | 14 | 1.157 | 6.0 | 0.02 |
| Siemens/DPC Immulite 2000/2500 | 14 | 1.329 | 11.2 | 0.05 |
| Roche Elecsys | 11 | 1.451 | 6.0 | 0.03 |
| Siemens Atellica IM | 8 | 1.225 | 2.9 | 0.02 |
| Siemens Centaur CP | 8 | 1.091 | 5.4 | 0.03 |
| bioMerieux, VIDAS TSH3 Ultrasensitive | 8 | 1.286 | 6.6 | 0.04 |
| Siemens Centaur XP/XPT | 9 | 1.297 | 12.3 | 0.07 |
| Siemens/DPC Immulite 1000 | 8 | 1.276 | 7.1 | 0.04 |




TDPA = 23.9%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Urea, mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5831 | 118.502 | 5.0 | 0.10 | 9.01 | 528 |
| Abbott Architect Urea Nitrogen 2 | 39 | 123.306 | 2.8 | 0.70 | 9.37 | 5 |
| Abbott Architect c systems | 37 | 123.678 | 2.6 | 0.65 | 9.40 | 4 |

| | | | |
|---|---|---|---|
| Your Result | 125.000 | SDI | 0.14 |
| | | RMSDI | Too Few |
| Mean for Comparison | 123.678 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 1.1 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 12.50% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Urease, kinetic | 4953 | 118.847 | 4.8 | 0.10 |
| Urease, end point | 342 | 117.418 | 5.8 | 0.46 |
| Ortho Vitros MicroSlide Systems | 210 | 113.538 | 3.2 | 0.32 |
| Urease, hypochlorite | 91 | 114.973 | 5.3 | 0.80 |
| Agappe - UREASE GLDH | 57 | 113.268 | 5.0 | 0.93 |
| Other Dry Chemistry | 47 | 125.484 | 3.1 | 0.72 |
| Abbott Architect Urea Nitrogen 2 | 39 | 123.306 | 2.8 | 0.70 |
| Beckman - Conductivity | 29 | 120.724 | 4.6 | 1.28 |
| Agappe - BERTHELOT | 10 | 116.083 | 4.2 | 1.91 |
| Diacetyl monoxime | 4 | 119.366 | 2.6 | 1.95 |
| O-Phthalaldehyde | 4 | 119.050 | 6.8 | 5.06 |
| Vitros DT60/DT60 II | 3 | 123.494 | 6.4 | 5.70 |




TDPA = 12.5%












RIQAS

UKAS PROFICIENCY TESTING 0010

# Uric Acid (Urate), mg/dl

| | N | Mean | CV% | $U_m$ | SDPA | Exc. |
|---|---|---|---|---|---|---|
| All Methods | 5388 | 9.323 | 4.3 | 0.01 | 0.60 | 590 |
| Uricase perox. no ascorb. ox. | 2211 | 9.301 | 4.6 | 0.01 | 0.60 | 278 |
| Abbott Architect c systems | 96 | 9.285 | 2.5 | 0.03 | 0.60 | 14 |

| | | | |
|---|---|---|---|
| ▲ Your Result | 9.300 | SDI | 0.02 |
| | | RMSDI | Too Few |
| Mean for Comparison | 9.285 | TS | 120 |
| | | RMTS | Too Few |
| | | %DEV | 0.2 |
| | | RM%DEV | Too Few |

| | |
|---|---|
| Acceptable limits derived from Biological Variation | N/A |
| Acceptable limits of performance for RIQAS | 10.60% |




| Method | N | Mean | CV% | $U_m$ |
|---|---|---|---|---|
| Uricase perox. no ascorb. ox. | 2211 | 9.301 | 4.6 | 0.01 |
| Uricase Perox. with ascorb. ox | 1437 | 9.444 | 4.0 | 0.01 |
| Uricase Perox. with ascorb. ox @ 546nm | 1038 | 9.249 | 3.5 | 0.01 |
| Ortho Vitros MicroSlide Systems | 216 | 8.882 | 2.8 | 0.02 |
| Uricase @ 293 nm | 180 | 9.271 | 2.1 | 0.02 |
| Uricase, catalase 340nm. | 106 | 9.303 | 2.1 | 0.02 |
| Agappe - URICASE - PAP | 39 | 9.820 | 3.1 | 0.06 |
| Abbott Architect Uric Acid 2 | 31 | 9.305 | 1.3 | 0.03 |
| Abbott Alinity Uric Acid 2 | 32 | 9.244 | 1.7 | 0.03 |
| Other Dry Chemistry | 24 | 10.125 | 4.7 | 0.12 |
| Agappe - URICASE - TOPS | 22 | 9.752 | 7.2 | 0.19 |
| Reduction methods | 8 | 9.502 | 1.7 | 0.07 |
| Vitros DT60/DT60 II | 4 | 9.759 | 19.1 | 1.17 |















RIQAS

UKAS PROFICIENCY TESTING 0010

| Analyte | Mean for Comparison | Your Result | SDI | RMSDI | %DEV | RM%DEV | TS | RMTS | Performance |
|---|---|---|---|---|---|---|---|---|---|
| Albumin | 2.871 | 2.700 | -1.09 | Too Few | -6.0 | Too Few | 68 | Too Few | |
| Alkaline Phosphatase | 355.591 | 304.000 | -1.29 | Too Few | -14.5 | Too Few | 61 | Too Few | |
| ALT (GPT) | 139.167 | 131.000 | -0.64 | Too Few | -5.9 | Too Few | 91 | Too Few | |
| Amylase, Pancreatic | 266.001 | 259.000 | -0.21 | Too Few | -2.6 | Too Few | 120 | Too Few | |
| Amylase, Total | 313.175 | 317.000 | 0.12 | Too Few | 1.2 | Too Few | 120 | Too Few | |
| AST (GOT) | 143.468 | 160.000 | 1.28 | Too Few | 11.5 | Too Few | 61 | Too Few | |
| Bile Acids | 43.472 | 47.800 | 0.67 | Too Few | 10.0 | Too Few | 89 | Too Few | |
| Bilirubin, Direct | 1.714 | 1.700 | -0.05 | Too Few | -0.8 | Too Few | 120 | Too Few | |
| Bilirubin, Total | 5.245 | 5.100 | -0.29 | Too Few | -2.8 | Too Few | 120 | Too Few | |
| Calcium | 12.063 | 12.300 | 0.39 | Too Few | 2.0 | Too Few | 113 | Too Few | |
| Chloride | 113.611 | 113.000 | -0.19 | Too Few | -0.5 | Too Few | 120 | Too Few | |
| Cholesterol | 286.671 | 286.000 | -0.04 | Too Few | -0.2 | Too Few | 120 | Too Few | |
| CK, Total | 522.993 | 517.000 | -0.16 | Too Few | -1.1 | Too Few | 120 | Too Few | |
| Creatinine | 4.525 | 4.880 | 1.02 | Too Few | 7.8 | Too Few | 71 | Too Few | |
| GGT | 164.412 | 167.000 | 0.14 | Too Few | 1.6 | Too Few | 120 | Too Few | |
| Glucose | 15.719 | 283.000 | ***329.04*** | Too Few | ***999.0*** | Too Few | ***10*** | Too Few | ▲ |
| HDL-Cholesterol | 96.439 | 96.000 | -0.04 | Too Few | -0.5 | Too Few | 120 | Too Few | |
| Iron | 231.371 | 224.000 | -0.52 | Too Few | -3.2 | Too Few | 100 | Too Few | |
| LD (LDH) | 355.290 | 360.000 | 0.17 | Too Few | 1.3 | Too Few | 120 | Too Few | |
| LDL-Cholesterol (Pilot) | 115.258 | 114.000 | -0.09 | Too Few | -1.1 | Too Few | 120 | Too Few | |
| Lipase | 60.075 | 60.000 | -0.01 | Too Few | -0.1 | Too Few | 120 | Too Few | |
| Lithium | 2.036 | 2.060 | 0.17 | Too Few | 1.2 | Too Few | 120 | Too Few | |
| Magnesium | 4.209 | 4.300 | 0.32 | Too Few | 2.2 | Too Few | 120 | Too Few | |
| Phosphate, Inorganic | 6.811 | 6.700 | -0.28 | Too Few | -1.6 | Too Few | 120 | Too Few | |
| Potassium | 6.109 | 6.100 | -0.04 | Too Few | -0.1 | Too Few | 120 | Too Few | |
| Protein, Total | 4.681 | 4.800 | 0.48 | Too Few | 2.5 | Too Few | 103 | Too Few | |
| PSA, Total | 14.965 | 14.200 | -0.34 | Too Few | -5.1 | Too Few | 119 | Too Few | |
| Sodium | 157.113 | 156.000 | -0.32 | Too Few | -0.7 | Too Few | 120 | Too Few | |
| Free T3 | 7.867 | 7.570 | -0.36 | Too Few | -3.8 | Too Few | 116 | Too Few | |
| Free T4 | 3.930 | 4.190 | 0.54 | Too Few | 6.6 | Too Few | 98 | Too Few | |
| TSH | 1.028 | 1.070 | 0.28 | Too Few | 4.0 | Too Few | 120 | Too Few | |
| Urea | 123.678 | 125.000 | 0.14 | Too Few | 1.1 | Too Few | 120 | Too Few | |
| Uric Acid (Urate) | 9.285 | 9.300 | 0.02 | Too Few | 0.2 | Too Few | 120 | Too Few | |

**ORMSDI N/A** **ORM%DEV N/A** **ORMTS N/A**

END OF REPORT



RIQAS

UKAS PROFICIENCY TESTING 0010